Know Cancer

or
forgot password


Phase 2
65 Years
N/A
Not Enrolling
Both
Multiple Myeloma

Thank you

Trial Information


Inclusion Criteria:



- newly diagnosed of multiple myeloma.

- Age > 65 years

- ECOG <= 3

- Written informed consent given at the time of randomization

- Patients with age <= 65 but not eligible for high dose treatment with stem cells
support

Exclusion Criteria:

- ECOG > 3

- current neoplasm..

- contraindications to use thalidomide

- peripheral neurophaty

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label

Outcome Measure:

To assess the efficacy

Outcome Description:

To compare the percentage of response in term of complete response, partial response, minimal and stable disease in the 2 arms o treatment

Outcome Time Frame:

from 8 to 12 months

Safety Issue:

No

Authority:

Italy: Ethics Committee

Study ID:

MM03

NCT ID:

NCT01274403

Start Date:

Completion Date:

Related Keywords:

  • Multiple Myeloma
  • Multiple Myeloma
  • Elderly patients
  • Multiple Myeloma
  • Neoplasms, Plasma Cell

Name

Location